Day: March 5, 2026

ATHENS, Greece, March 05, 2026 (GLOBE NEWSWIRE) — Capital Clean Energy Carriers Corp. (the “Company”, “CCEC”, “we” or “us”) (NASDAQ: CCEC), an international owner of ocean-going vessels, today released its financial results for the fourth quarter ended December 31, 2025. Key Quarterly HighlightsOrdered three latest-technology LNG carriers with deliveries in 2028 and 2029 Concluded the sale of a 13,696 TEU container vessel, the M/V Buenaventura Express Took delivery of our first LCO2/multi-gas carrier, the Active Announced dividend of $0.15 per share for the fourth quarter of 2025Key Financial Highlights (continuing operations)  Three-month period ended December 31,  2025 2024 Increase/(Decrease)Revenues $98.3 million $97.6 million 0.7%Expenses $44.8 million $44.5 million 0.7%Interest expense and finance cost $23.9...

Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year period Non-GAAP earnings* of $0.24 per diluted share Fourth quarter cash from operations of $38.0 million increased 97% 2026 financial guidance reflects continued above-market revenue growth, higher earnings and robust cash generationDURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2025, and provided its financial guidance for full-year 2026. “Our team delivered strong fourth quarter performance, concluding an important year in which we strengthened...

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026 Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026 Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., March 05, 2026 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates. “Throughout 2025, we translated strategy into disciplined execution and meaningfully advanced our pipeline,” said Aoife Brennan, M.B.,...

Fourth Quarter and Full Year Results Exceeded Top- and Bottom-line Guidance Comparable Sales Increased 8% in the Fourth Quarter and 5% for the Full Year Fourth Quarter and Full Year Adjusted Operating Income Significantly Exceeded Expectations Initiates First Quarter and Fiscal 2026 GuidanceREYNOLDSBURG, Ohio, March 05, 2026 (GLOBE NEWSWIRE) — Victoria’s Secret & Co. (“VS&Co” or the “Company”) (NYSE: VSCO) today reported financial results for the fourth quarter and fiscal year ended January 31, 2026. Hillary Super, VS&Co Chief Executive Officer, said, “We delivered an exceptional fourth quarter and a standout year, exceeding top- and bottom-line guidance with broad based outperformance across brands, channels and geographies. We drove meaningful acceleration in the second half of the year, with fourth quarter...

Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM  Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments.  “The fourth quarter of 2025 marked the completion of an incredible year for Lexicon,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and...

Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarter More than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025 Ended 2025 with $190.7 million in cash and cash equivalents, an increase of $33.2 million from the third quarter Recorded second consecutive quarter of profitabilityMORRISVILLE, N.C., March 05, 2026 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the full year ended December 31, 2025. The company will also host a webcast at 8:30 a.m. ET on March 5, 2026, to discuss its financial results and provide a corporate update. Dr....

NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) — Teads Holding Co. (Nasdaq: TEAD) (“Teads” or the “Company”) announced today financial results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Key Financial Metrics1:  Three Months EndedDecember 31,   Twelve Months EndedDecember 31,(in millions USD)   2025       2024     % Change     2025       2024     % ChangeRevenue $ 352.2     $ 234.6     50 %   $ 1,300.5     $ 889.9     46 %Gross profit   120.4       56.1     115 %     429.1       192.1     123 %Net loss   (428.2 )     (0.2 )   NM     (517.1 )     (0.7 )   NMNet cash provided by operating activities   7.3       42.7     (83 )%     7.6       68.6     (89 )%                       Non-GAAP Financial Data*                      Ex-TAC gross profit   151.8       68.3     122 %     529.7       236.1     124 %Adjusted...

LIBERTY, Mo., March 05, 2026 (GLOBE NEWSWIRE) — Ferrellgas Partners, L.P. (OTC: FGPR) (“Ferrellgas” or the “Company”) today reported financial results for its 2026 second fiscal quarter ended January 31, 2026. “Our team’s preparation at the beginning of fiscal 2026 enabled us to achieve strong second-quarter results,” said Tamria Zertuche, President and CEO. “Extended cold weather across much of the eastern region, combined with warmer conditions in the west, created both challenges and opportunities for the beginning of the winter heating season. Our employee-owners showed exceptional adaptability by reallocating personnel and resources to meet increased demand while continuing to drive growth and manage expenses. As a result, we achieved expanded margins, increased profit and are well positioned for the upcoming quarter and the...

Q4 total sales grew 11%, and comparable store sales increased 4%  Q4 net income was $310 million, and diluted EPS was $4.84 FY25 total sales grew 9%, and comparable store sales increased 2% FY25 net income was $610 million, and diluted EPS was $9.51 Excluding expenses associated with bankruptcy acquired leases:Q4 Adjusted EBIT margin increased 100 basis points versus Q4 of FY24 Q4 Adjusted EPS increased 21% to $4.99, versus guidance of $4.50 to $4.70 FY25 Adjusted EBIT margin of 8.0%, an increase of 80 basis points versus FY24 FY25 Adjusted EPS of $10.17, an increase of 22% versus FY24BURLINGTON, N.J., March 05, 2026 (GLOBE NEWSWIRE) — Burlington Stores, Inc. (NYSE: BURL), a nationally recognized off-price retailer of high-quality, branded apparel, footwear, accessories, and merchandise for the home at everyday low prices,...